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Abstract Hybridomas producing monoclonal anti-idiotypic antibodies (anti-id MAbs) to N-acetylglucosaminyl-B1-4-N_acetylmur~yl-~~yl-~- 
isoglutamine (GMDP) were developed. Three clones of hybridomas demonstrated the properties characteristic for the Ab2# type of anti-id antibody: 
they bound to Fab-fragments of high-affinity MAb to GMDP, dosedependent inhibition of this binding by GMDP was observed; immunization 
of mice with these MAbs resulted in production of GMDP-specific antibodies. When these antibodies were used to stain blots from SDS-PAGE of 
macrophage lysate, the same receptor proteins were specifically stained as upon staining with ‘zsI-labelled GMDP derivative. 
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1. Intruduction 
Muramyldipeptide (MDP) is the minimal structure of the 
bacterial cell wall capable of replacing mycobacteria in 
Freunds’ complete adjuvant [l]. MDP and its analogues, con- 
taining the N-acetylglucosamine residue, demonstrate a variety 
of biological activities, in particular, adjuvant effect [2,3], in- 
duction of non-specific resistance to infections [4,5], and som- 
.nogenic activity [6]. The molecular basis of biological activity 
of mummy1 peptides (MPs) is poorly understood, but the ma- 
jority of data favors a receptor-mediated mechanism [7-lo]. 
Macrophages are shown to be the main target of MPs [4]. 
The number of cell surface receptors for MPs is low, making 
their isolation and structural analysis difficult [7,8]. Like in 
studies of receptors of other biologically active ligands, mono- 
clonal antibodies to GMDP-receptors could be of great aid, but 
their production by traditional procedures is hardly achieved. 
Not long ago an alternative approach was developed based 
on the production of anti-idiotypic antibodies (anti-id) to corre- 
sponding ligands, capable of binding to ligand receptors. This 
approach is based on the Jeme theory of idiotypic network, 
claiming that the immune system consists of a set of interacting 
idiotypes and anti-idiotypes [ 111. According to this theory for 
each exogeneous epitope an anti-id antibody exists mimicking 
the so-called internal image of this epitope by its hypervariable 
region. This antibody is designated as Ab2/3 [12]. 
Anti-id antibodies can be induced by immunization with 
anti-ligand antibodies, imitating the binding site of the recep- 
tor. Using this approach monoclonal and polyclonal antibodies 
to a number of receptors were produced [13-161. The crucial 
step in obtaining anti-id MAbs capable of binding to the ligand 
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GMDP-OVA, GMDP conjugated to ovalbumin; GMDP-AL, GMDP 
conjugated to poly-Lys-poly-Ala polymer; MeBSA, methylated bovine 
serum albumin. 
receptor is identifying among hybridoma those clones produc- 
ing antibodies of the Ab2# type to paratope-associated epi- 
topes. In this study we developed murine hybridomas produc- 
ing MAbs to the GMDP-binding site of mouse E611.2 MAb, 
and identified three antibodies mimicking the internal image of 
GMDP. 
2. Materials and methods 
2.1. Mice and reagents 
Female Balb/c and Fl (CBAxC57BL/6)mice, 10-12 weeks old, were 
purchased from Stolbovaya breeding house. (Moscow region). 
GMDP, GMDP-Lys and GMDP-AL were synthesized by E. 
Makarov in the Laboratory of Peptide Chemistry, Shemyakin- 
Ovchinnikov Institute of Bioorganic Chemistry, Moscow, in accord- 
ance with earlier the developed procedure [2,24]. GMDP-OVA conju- 
gate was synthesized as in [17]. 
Streptoavidin-horseradish peroxidase conjugate was a kind gift from 
Dr. V Kovalenko, Shemyakin-Ovchinnikov Institute of Bioorganic 
Chemistry. 
Cell culture reagents were purchased from Gibco (Scotland). 
2.2. Production and purification of Fab-fragments of E6ll.2 MAb 
Homogeneous E6/1.2 MAb was isolated from murine ascites by 
afIinity chromatography on immobilized GMDP-Lys [ 11. Papain hy- 
drolysis of MAb was performed as in [19]. Briefly, 150 pl 10x PBS, 
70 ~10.1 M L-cysteine, 70 ~10.02 M disodium EDTA and 40 ,ug papain 
in 70 ~1 PBS were added to 9 mg of affinity-puritied E611.2 MAb in 1.5 
ml PBS. The mixture was incubated for 2.5 h at 37°C with occasional 
shaking. The reaction was stopped by incubation for 30 min at room 
temperature with 70 ~1 0.15 M iodoacetamide. Papain digest was 
dialyzed against 0.05 M Tris-HCl, pH 7.5, and centrifuged at 10,000 x g 
for 30 min at 4°C. The supematant was applied to an FPLC Mono-Q 
5/5 column, equilibrated with 0.05 M Tris-HCl, pH 7.5. Non-bound 
material was washed out with the same buffer and elution was carried 
out with a 0 to 1 M gradient of sodium chloride. Each fraction was 
analyzed by competition ELISA [17]. Peaks I and II (Fig. l), containing 
the main part of GMDP-AL-binding activity, were dialyzed against 
PBS, pH 7.4. Each peak (30 ~1) was analyzed by SDS-PAGE [20] on 
a 10% gel under reducing and non-reducing conditions. 
Purified Fab-fragments were concentrated by ultrafiltration using 
PM 10 membrane and stored in PBS, containing 0.02% NaN,, at 4°C. 
2.3. Synthesis of Fab-MeBSA 
Fab-fragments of E60.2 MAb (15 vg, 0.1 ~01) in 2 ml PBS were 
activated for 1 min at 18’C with 320 mg (2 mmol) EDC and 13.6 mg 
(0.1 mmol) I-hydroxybenzotriazole, dissolved in 5 ml DMFA. Acti- 
vated fragments were mixed with 6.7 mg (0.1~01) MeBSA in 5 ml PBS 
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and stirred overnight at 4°C. The reaction was stopped by dialysis 
against PBS, pH 7.4. The conjugate was stored in 20% glycerol at 
-20°C. 
2.4. Immunization and hybridization 
Balblc mice were immunized bv in. iniections of 200 ue. Fab-MeBSA 
conjugate. Two injections were made w&h a two-week interval in com- 
plete Freunds’ adjuvant followed by three injections at one-week inter- 
vals in incomplete Freunds’ adjuvant. Three weeks after the Iifth immu- 
nization the mouse with the highest titer of anti-Fab antibodies was 
boosted during three consecutive days by i.p. injections with 100 pg 
Fab-MeBSA in PBS. Hybridization of splenocytes (5 x 10’ cells) with 
SPUO myeloma cells (10’ cells) was carried out by a standard procedure 
using PEG 6000 [25]. The suspension of hybrid cells in RPM1 1640, 
containing 20% FCS, was dispersed onto wells of four 96-well mi- 
crotiter plates. The next day half of the culture medium was exchanged 
for HAT-medium. Twelve to fourteen days later supematants from 
growing clones were screened for specific antibody production. 
2.5. Binding ELISA 
Supematants from hybrid clones were screened for production of 
anti-E6il.2 MAb by solid-phase ELISA using E6/1.2 Fab-fragments, 
biotinylated as in [22]. 
Supematants were absorbed onto wells of 96-well microtiter plates 
at 4°C overnight. Remaining binding sites were blocked by 1 h incuba- 
tion with 200 ~1 per well of 0.1% gelatin in PBS. After washing with 
PBST 100 ~1 of biotinylated E611.2 Fabs, diluted 1:2,000 with PBS, 
were introduced. The incubation was carried out for 1 h at room 
temperature. Plates were washed with PBST and incubated for 1 h at 
room temperature with 100 pi/well of 1: 2,000 dilution of streptoavidin- 
HRP conjugate in PBS. After washing lOO@ of OPD solution (1 mgfml) 
in 1% citrate buffer, pH 4.5, containing 0.05% H20t, were added. The 
reaction was stopped 15-30 min later by addition of 100 @well of 
1 M H,SO.,. Optical density at 492 nm was measured. 
2.6. Competition ELISA 
GMDP-OVA (40 pg/ml) or GMDP-AL (10 @ml) in PBS were 
absorbed onto wells of microtiter plates for 1 h. Washing and blocking 
of remaining binding sites were performed as described in section 2.5. 
Fractions from the Mono-Q 5/5 column or serial twofold dilutions of 
anti-id MAbs (50 pi/well) in PBS and 50 ~1 of biotinylated E60.2 Fabs 
(1:4,000 dilution in PBS) were added. After 1 h incubation microtiter 
plates were washed and incubated for 1 h with 100 ~1 1: 2,000 dilution 
of streptavidin-HRP. The reaction was visualized as described in seo 
tion 2.5. All incybations were carried out at room temperature. 
Inhibition index (Z, 8) was calculated from: 
I= 
A, - 4 
TX 100 
Ao 
where A, and A, are optical densities of samples without or with inhib- 
itor, respectively. 
2.7. Purification and characterization f anti-idMAbs 
Hybridomas were grown in ascites of Balb/c mice. Mice were admin- 
istered with 0.5 ml pristane and 14 days later inoculated with hybrid- 
oma cells (2 x lo6 cells per mice). 
MAbs were purified from ascites fluid by using affmity chromatogra- 
phy. E6/1.2 MAb Fab-fragments were immobilized on CNBr-activated 
Sepharose-4B according to instructions of the manufacturer. Elution 
was performed with 0.1 M glycine-HCl buffer pH 3.0. The purity of 
MAbs was characterized by SDS-PAGE in a 10% gel [20]. Isotypes and 
subtypes of MAbs were characterized by using commercial monospeci- 
fit rabbit anti-mouse immunoglobulin antibodies, conjugated to HRP. 
2.8. Induction of A63 by anti-id MAbs to GMDP 
Groups of 5 female Fl (CBAxC57Bl/6) mice were administered i.p. 
5 times with anti-id MAbs, 10 &mice in 0.2 ml PBS. The first two 
injections were made in complete Freunds adjuvant, the rest in PBS. A 
week after the fifth injection mice sera were screened for antibodies 
specific to GMDP by ELISA as described in [17]. GMDP-AL (20 
&ml) was used as antigen. Serum from non-immune mice was used 
as a control. 
2.9. Isolation of membrane fraction of WEHI- cells 
WEHI- cells were erown in mastic flasks in RPM1 1640 medium. 
supplemented with 10% fetal cat serum, 2 mM L-glutamine, 0.05 mM 
2-mercaptoethanol. 
Cells were dissociated from plastic by Versene solution (37°C 
20 min), washed with PBS and lysed by 0.002 M Tris-HCl, pH 7.5, 
containing 0.002 M CaCl, and 0.001 M phenylmethylsulfenyl fluoride. 
Intact cells and nuclei were sedimented by centrifugation (1,000 x g, 10 
min). Membranes were pelleted by centrifugation at 105,000 x g for 60 
min. 
2.10. Immunostaining of WEHI- cell membrane proteins with anti-id 
MAb 
Membranes (50 pg of protein) were dissolved in sample buffer for 
SDS-PAGE. Identical quantities of sample were introduced into several 
wells of the polyacrylamide gel. Electrophoresis was carried out accord- 
ine to Laemmli I201 on a 7.5% slab gel. Proteins were blotted onto a 
n&cellulose membrane according to-Burnett [21]. After incubating the 
membrane with 1 mg/ml BSA in PBS (4’C, 18 h) it was cut into strips 
along the sample lanes. Individual strips were incubated with: 
(a) 100 pg/ml solution of C5/F8 MAb in PBS; (b) 100 @ml solution 
of LNKB-1 MAb (IgG2b) to human IL 2. 
The antibodies bound to membrane proteins were visualized with 
HRP-coniueated rabbit anti-mouse immunoalobulin antibodies (1: 500 
dilution, DAK0 PATTS, Denmark) and the mixture of 3,3’-diamino- 
benzidine with 4chloronaphtol [22]. The strip with molecular weight 
markers was stained with 0.5% Amid0 black in methanol/acetic acid/ 
water (50: 10:40). 
3. Results and discussion 
Not long ago we described the development of hybridoma 
clone E611.2, producing high aflinity murine IgGl (z) MAb (& 
2 x 10’ M-‘) specific to GMDP [17]. Inhibition analysis re- 
veaIed that E611.2 antibody besides GMDP could specifically 
bind GMDP-Lys and to a lesser extent L-GMDP Interaction 
of E611.2 MAb with GMDP was slightly inhibited by disaccha- 
ride GlcNAc-MurNAc, but not by MDP, GlcNAc, MurNAc 
or dipeptide Ala-n-iGln. Thus, both sugar and peptide frag- 
ments of the molecule seemed to be crucial for GMDP binding, 
the most important being the intact disaccharide moiety and the 
Ala residue. 
The aforementioned properties enabled us to use the E611.2 
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Fig. 1, Ion-exchange chromatography of MAb E6/1.2 Fab-fragments 
on FPLC Mono Q 5/5 column. Fractions positive in solid-phase ELISA 
are shaded. 
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Fig. 2. SDS-PAGE of E6/1.2 Fab-fragments in 10% gel. Lanes 2 and 
4, peak I; lanes 1 and 5, peak II under reducing or non-reducing 
conditions, respectively. Lane 3, protein standards. 
antibody for the production of monoclonal anti-id antibodies 
to GMDP mimicking its internal image. 
Fab-fragments of E6/1.2 MAb were used to mount an anti-id 
response in Balb/c mice. To obtain these fragments the E6/1.2 
antibody was purified from ascites by affinity chromatography 
on immobilized GMDP-Lys [17] and subjected to papain hy- 
drolysis [19]. Purification of Fab-fragments was achieved by 
DEAE-chromatography (Fig. 1). GMDP-binding activity 
eluted in two peaks. SDS-PAGE analysis (Fig. 2) revealed that 
Fab-fragments were eluted with flow-through fractions (peak 
I) whereas non-digested IgG eluted with NaCl gradient (peak 
II). 
E6/1.2 Fab-fragments were conjugated to methylated BSA 
(Fab-MeBSA) in order to increase their immunogenicity. Ac- 
cording to ELISA this conjugate retained the ability of E6/1.2 
MAb to bind GMDP, confirming the preservation of native 
structure of GMDP-binding site on Fab-fragments. 
Balb/c mouse was administered 5 times with Fab-MeBSA, 
and splenocytes were fused with SP210 myeloma. Positive hybr- 
idoma clones were selected 12-14 days later according to the 
ability of antibodies to interact with biotinylated E6/1.2 Fab- 
fragments in binding ELISA. In total 26 hybridoma clones were 
selected. 
In order to identify clones producing MAbs to paratope- 
associated epitopes, the potency of hybridoma supemates to 
Table 1 
Properties of monoclonal anti-idiotypic antibodies to GMDP 
Clone Isotype, Binding Induction Type 
subtype constant to of Ab3, 
MAb E6l1.2 specific 
(M-l) to GMDP 
B4/B6 
C5lF3 
CYF8 
Cl0 
D3lG4 
El/B2 
E6lF2 
E9lC2 
IgM 
IgG2b 
IgG2b 
IgG3 
IgM 
IgGl 
IgM 
IgGl 
n.d. 
3.2 x lo7 
1.2 x lo7 
n.d. 
n.d. 
5.5 x lo7 
n.d. 
2.1 x 10’ 
Y 
5 
Y 
Y 
B or Y 
Y 
Y 
inhibit binding of biotinylated E6/1.2 Fab-fragments to 
GMDP-OVA was evaluated. According to competition ELISA 
seven positive clones were identified. 
Hybridomas positive in both assays were cloned by the lim- 
iting dilution procedure. After recloning 8 clones, secreting 
MAbs to paratope-associated epitopes of E611.2 MAb, were 
selected. Isotypes and subtypes of anti-id MAbs were deter- 
mined by using commercial antisera. For some of these, alIinity 
to E6/1.2 MAb was determined by the procedure of Beatty et 
al. [26]. Properties of obtained MAbs are summarized in 
Table 1. 
Among anti-id antibodies, binding of which to anti-ligand 
antibodies can be inhibited by ligand, few types are known to 
be present. Only one type, known as Ab@, in fact mimics the 
internal image of the ligand. The most simple approach to 
identify Ab@ type MAb includes the study of specificity of 
antibody response to anti-id MAb, because administration of 
Ab2# has to result in the accumulation of ligand-specific anti- 
bodies (anti-anti-id antibodies, Ab3) [18]. In our case produc- 
tion of anti-GMDP antibodies had to be expected. 
To induce the formation of Ab3 female Fl (CBAxC57BY6) 
mice (groups of 5 animals) were immunized 5 times with anti-id 
MAbs to GMDP. Serum from each mice was assayed for 
GMDP-speci8c antibodies by using direct and competition 
solid-phase ELISA [ 171. GMDP-AL (20 @ml) was used as an 
antigen. In control samples, serum taken from non-immune 
mouse was substituted for serum from immune animals. Inhibi- 
tion of Ab3 binding to GMDP-AL in the presence of free 
GMDP was evaluated as described above. 
Though serum from any immtme mouse to a certain extent 
bound to GMDP-AL (data not shown), specific dose-depend- 
ent inhibition was observed only for serum from mice immu- 
nized with MAbs C5/F3, C5/F8 and El/B2 (Fig. 3). It should 
be noted that for these three anti-id MAbs specific, dose-de- 
pendent inhibition was observed with sera from all mice in the 
corresponding group. 
4% 
100 -
80 - 
60 - 
a 
0 
1 2 4 0 ft 32 64 12S260600WOO 
Concentration of anti-id mAb, nM 
Fig. 3. Inhibition analysis of biotinylated E6/1.2 Fab-fragments binding 
to GMDP-OVA in the presence ofanti-id MAbs: El/B2 (0) C5/F8 (o), 
ClO/F9 (n), E9/C2 (o), B4/B6 (x). E61F2 (n) or D31G4 (0). 
16 T Yu. Mareeva et al. IFEBS Letters 3S6 (1994) 13-16 
A B 
Fig. 4. Blot from SDS-PAGE of membranes from WEHI- cells. Stain- 
ing in the absence (A) or presence (B) of GMDP with MAb C5/F8 
followed by HRP-conjugated rabbit anti-mouse immunoglobulin anti- 
bodies and a mixture of 3,3’-diaminobenzidine with 4-chloronaphtol. 
In order to investigate the possibility of using these antibod- 
ies in studying GMDP-receptors we compared the array of 
proteins of WEHI- cells capable of binding GMDP and MAb 
CYFS. WEHI- cells were shown not so long ago to have 
intracellular GMDP-binding sites [30]. Cells were lysed by os- 
motic shock, and the membrane fraction was isolated and sub- 
jected to SDS-PAGE analysis. A blot from the gel was incu- 
bated with purified C5/F8 anti-id MAb. Subsequent incubation 
with HRP-conjugated anti-mouse immunoglobulin antibodies 
and peroxidase substrate revealed few proteins binding MAb 
CYF8, with molecular weights 32-34,45 and less than 30 kDa 
(Fig. 4A). Weak staining of 36 and 180 kDa bands was ob- 
served as well. The specificity of binding was confirmed by 
inhibition analysis: when the incubation with MAb was carried 
out in the presence of GMDP no binding occurred (Fig. 4B). 
No binding was observed also when irrelevant MAb of the 
same IgG subtype was substituted for C5/F8 MAb. It should 
be noted that proteins of similar molecular weight were identi- 
fied as specific intracellular GMDP-receptors of murine perito- 
neal macrophages and WEHI- cells by affinity labelling tech- 
nique (T.N. Golovina et al., submitted for publication). 
The data obtained enable us to conclude that hybridomas 
C5lF3, C5lF8 and El/B2 produce anti-id MAbs, classified as 
Ab2@, mimicking the internal image of GMDP. To our knowl- 
edge this is the first report describing the production of anti- 
idiotypic MAbs to muramyl peptide. 
Acknowledgements: The authors are grateful to Dr. T.M. Andronova 
and E.A. Makarov for providing mummy1 peptides, and to Dr. V. 
Kovalenko for the streptavidin-horseradish peroxidase conjugate. 
References 
[l] Elloux, F., Adam, A., Ciorbaru, R. and Lederer, E. (1974) Bio- 
them. Biophys. Res. Commun. 59, 1317-1325. 
[2] Rostovtseva, L.I., Andronova, T.M., Mal’kova, VP., Sorokina, 
LB. and Ivanov, VT. (1981) Bioorg. Chem. (Russ.) 7, 1843-1858. 
[3] Ivanov, VT. (1984) Voprosy Meditsinskoi Khiiii (Russ.) 30,23- 
31. 
[4] Adam, A., Petit, J.-F., Lefrancier, P. and Lederer, E. (1981) Mol. 
Cell. B&hem. 4L27-47. 
[5] Adam, A. and Lederer, E. (1984) Med. Res. Rev. 4, 111-152. 
[6] Krueger, J.M., Pappenheimer, J.R. and Kamovsky, M.L. (1982) 
Proc. Natl. Acad. Sci. USA 79, 6102-6106. 
[7] Silverman, D.H.S., Krueger, J.M. and Kamovsky, M.L. (1986) 
J. Immunol. 136,2195-2201. 
[8] Kaydalov, A.A., U&in, Yu.N., Andronova, T.M., Tsetlin, V.I. 
and Ivanov, VT. (1987) Bioorg. Chem. (Russ.) 13, 1523-1529. 
[9] Tenu, J.-P., Adam, A., Souvannavong, V., Yapo, A., Petit, J.-F. 
and Douglas, K. (1989) Int. J. Immtmopharmacol. 11, 653661. 
[lo] Richerson, H.B., Adam, P.A., Iwai, Y. and Barfknecht, C.F. 
(1990) Am. J. Respir. Cell Mol. Biol. 2, 171-181. 
[ll] Jeme, N.K. (1974) Ann. Inst. Pasteur bnrnunol. 125C, 373-389. 
[12] Poskitt, DC., Jean-Francous, M.J.B., Tumbull, S., Macdonald, 
L. and Yasmeen, D. (1991) Immunol. Cell. Biol. 69, 61-70. 
[13] Sege, K. and Peterson, P.A. (1978) Proc. Natl. Acad. Sci. USA’75, 
2443-2447. 
[14] Couraud, J.-Y., Escher, E., Regoli, D., Imhoff, V., Rossignol, B. 
and Pradelles, P. (1985) J. Biol. Chem. 260, 946-9469. 
[15] Lombes, M., Edelman, I.S. and Erlanger, B.F. (1989) J. Biol. 
Chem. 264, 2528-2536. 
[16] Taub, R. and Greene, MI. (1992) Biochemistry 31,7431-7435. 
[17] Mareeva, T.Yu., Kotova, O.V., Makarov, E.A., Andronova, T.M. 
and Nesmeyanov, VA. (1993) Bioorg. Chem. (Russ.) 19,555-561. 
[18] Schick, M.R. and Kennedy, R.C. (1989) Methods Enxymol. 178, 
3648. 
[19] Parham, P. (1986) in: Handbook of Experimental Immunology 
(Weir, D.M., Ed.) Vol. 1, pp. 14.1-14.23, Blackwell, Oxford. 
[20] Laemmli, U.K. (1970) Nature 227, 680-685. 
[21] Bahr, G.M., Carelli, C., Audibert, F., Modabber, F. and Chedid, 
L. (1982) Mol. Immunol. 19, 737-745. 
[22] Vilija, P., Krohn, K. and Tuohimaa, P. (1985) J. Immunol. Meth- 
ods 76, 73-83. 
Mescheryakova, E.A., Guryanova, S.V., Makarov, E.A., 
Andronova, T.M. and Ivanov, V.T. (1991) Bioorg. Chem. (Russ.) 
17, 1157-1165. 
Rar, VA., Makarov, E.A., Yurovsky, V.V., Mescheryakova, 
E.A., Andronova, T.M. and Ivanov, VT. (1990) Bioorg. Chem. 
(Russ.) 16, 904915. 
Kohler, G. and Milstein, C. (1975) Nature 256, 495-497. 
Beatty, J.D., Beatty, B.G. and Vlahos, W.G. (1987) J. Immunol. 
100, 173179. 
Bradford, M.M. (1976) Anal. B&hem. 72, 248-254. 
Burnett, W.N. (1981) Anal. Biochem. 112, 195. 
Young, P.R. (1989) J. Immunol. Methods 121, 295-296. 
Sumaroka, M.V., Litvinov, I.S., Khaidukov, S.V., Golovina, 
T.N., Kamraz, M.V., Komal’eva, R.L., Andronova, T.M., 
Makarov, E.A., Nesmeyanov, VA. and Ivanov, V.T. (1991) FEBS 
Lett. 95, 8-50. 
